Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund.

Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.

CNBC’s Angelica Peebles and Novo Nordisk CEO Lars Fruergaard Jørgensen join 'Squawk Box' to discuss the company's quarterly ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Incyte has a strong track record of revenue growth and a robust pipeline, targeting over 10 high-impact product launches by ...

Encoded’s layoffs will mostly affect its technology and early-stage research and development functions. The move is expected ...

sNDA accepted for Priority Review Datopotamab deruxtecan (AstraZeneca and Daiichi Sankyo) TROP2-directed DXd antibody drug conjugate Treatment of adults with locally advanced or metastatic ...

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

Moderna Inc.’s stock fell 2.9% early Friday, after the biotech posted a wider-than-expected fourth-quarter loss and offered ...